Arix Bioscience

Investor type Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 27
Average round size
The average size of a deal this fund participated in
Portfolio companies 19
Rounds per year 3.86
Lead investments 11
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 7
Key employees 5

Areas of investment

  • Biotechnology
  • Pharmaceutical
  • Health Care
  • Therapeutics
  • Medical

In 2015 was created Arix Bioscience, which is appeared as Corporate Investor. The main office of represented Corporate Investor is situated in the London. The company was established in Europe in United Kingdom.

The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the Arix Bioscience, startups are often financed by UBS Asset Management, SV Health Investors, OrbiMed. The meaningful sponsors for the fund in investment in the same round are OrbiMed, Lundbeckfonden Ventures, Sofinnova Investments. In the next rounds fund is usually obtained by iBank, Woodford Investment Management, UCLB.

Besides them, we counted 5 critical employees of this fund in our database.

For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in some founders of portfolio startups. If startup sums 3 or 4 of the founder, the chance for it to be financed is low. We can highlight the next thriving fund investment areas, such as Collaboration, Therapeutics. Among the most popular portfolio startups of the fund, we may highlight Atox Bio, VelosBio, Imara. Besides, a startup needs to be aged 4-5 years to get the investment from the fund.

The important activity for fund was in 2017. Despite it in 2019 the fund had an activity. The increased amount of exits for fund were in 2018. This Arix Bioscience works on 2 percentage points less the average amount of lead investments comparing to the other organizations. The fund is constantly included in 2-6 investment rounds annually. Speaking about the real fund results, this Corporate Investor is 40 percentage points more often commits exit comparing to other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Arix Bioscience:
Typical Co-investors
Arix Bioscience is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Arix Bioscience:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Bizdom Cleveland, Ohio, United States
Estlander & Partners -
Fi Capital Beijing, Beijing, China
Heyi Asset Management China, Shanghai
InvestorLoft Colorado, Denver, United States
Long Focus Capital -
Modernization and Technology Development Fund -
Mustedanagic & Plott Brothers GbR -
Otsuka Shokai Japan, Tokyo
Praktikerinvest Stockholm, Stockholm County, Sweden
Relan Global Management LLC California, Los Gatos, United States
Singular -
Symantec Arizona, Tempe, United States
Techstars Mobility Accelerator Detroit, Michigan, United States
Telogis Aliso Viejo, California, United States
The Foundry California, Menlo Park, United States
UBS Asset Management England, London, United Kingdom
Yuanchi Touzi China, Shanghai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Sorriso Pharmaceuticals

$31M22 Dec 2021 San Diego, California, United States


$36M15 Dec 2021 Paris, Ile-de-France, France

Disc Medicine

Health Care
$90M02 Sep 2021 Cambridge, Massachusetts, United States

Artios Pharma

Medical Device
$150M27 Jul 2021 Cambridge, England, United Kingdom

Pyxis Oncology

Health Care
$152M30 Mar 2021 Boston, Massachusetts, United States

Aura Biosciences

Health Care
$80M22 Mar 2021 Cambridge, Massachusetts, United States

GenSight Biologics

Health Care
$25M22 Oct 2020 Paris, Ile-de-France, France


$137M08 Jul 2020 -

Amplyx Pharmaceuticals

Clinical Trials
$53M19 May 2020 San Diego, California, United States
Disc Medicine Raises $90M in Series B Funding

– Disc Medicine from Cambridge MA develops therapeutic candidates for hematology.
– Series B $90M round was led by OrbiMed and attracted new investor – Arix Bioscience as well as existing investors Atlas Venture, Novo Holdings and Access Biotechnology.
– The new investment will be aimed at developing the company’s hematology pipeline of therapeutic candidates.

Pyxis Oncology Raises $152M Series B Round

– Pyxis Oncology from Longwood Fund has closed a $152m Series B financing.
– The round was led by Arix Bioscience and co-led by RTW Investments, LP.
– New investors included Perceptive Advisors, RA Capital Management, Pfizer Ventures, BVF Partners, L.P., Janus Henderson Investors, Cormorant Asset Management, HBM Healthcare Investments, funds managed by Tekla Capital Management LLC, Acuta Capital Partners, Ridgeback Capital Investments, Surveyor Capital (a Citadel company), Laurion Capital Management, Logos Capital and LifeSci Venture Partners.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Arix Bioscience?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: